TOMI Environmental Solutions, Inc. Reports Third Quarter 2020 Financial Results

FREDERICK, Md., Nov. 12, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), is a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products - a hydrogen peroxide-based mist and fog comprised of ionized Hydrogen Peroxide (iHP), announced its results for the third quarter of 2020.

TOMI Chief Executive Officer, Dr. Halden Shane stated, “We are a company that strives for SteraMist to become the gold standard in its industry, and I report another major milestone with revenues exceeding $21 million for our current calendar year. The third quarter also continued the trend of year over year revenue growth as SteraMist continues to see widespread adoption.   We have been pleasantly surprised to see that new clients in a number of the new verticals targeted by our commercial division are proving to be faster in integrating SteraMist into their protocol compared to blue-chip clients that adhere to stringent protocol and procedures. On the other hand, the TOMI Service Network and Healthcare Divisions faced persistent headwinds in the quarter as a number of potential clients elected to continue to utilize harsh chemical disinfectants and low-cost delivery systems. We anticipate these industries will increasingly see negative affects of these disinfectants and increasingly seek SteraMist to be their permanent solution, a trend that we have already seen as we begin the fourth quarter, as many of these companies are our either returning to or starting to use SteraMist. We also continued to make strides on the product development and intellectual property front with the SteraBot and SteraPack which will provide more differentiation in our product line and a competitive advantage in the marketplace. Management is adding executive sales division leaders and executing a plan for all divisions to grow consistently, both domestically and internationally, as we strive to innovate for a safer world.”

Financial Results for the Three Months Ended September 30, 2020 compared to September 30, 2019

  • Total net revenue was $4,292,000 compared to $1,600,000, representing an increase of $2,692,000, or 168%.
    • SteraMist® equipment-based revenues was $2,945,000 and $669,000, respectively, representing an increase of $2,276,000 or 340%
    • SteraMist® BIT Solution-based revenues was $732,000 and $259,000, respectively, representing an increase of $473,000 or 183%
    • Service-based revenue was $615,000 and $672,000, respectively, representing a decrease of $57,000 or 8%.
    • Domestic revenue was $3,446,000 and $1,288,000, respectively, representing an increase of $2,158,000, or 168%.
    • International revenue was approximately $846,000 and $312,000, respectively, representing an increase of $534,000 or 171%.
  • Gross margins were 66.1% compared to 71.3%. The lower gross profit is attributable to the product mix in sales.
  • Income from operations was $1,096,000, compared to a Loss from operations of ($188,000), representing an increase of $1,284,000.
  • Net Income was $1,019,000, or $0.06 on a per share basis compared to a Net loss of ($237,000), or ($0.02) on a per share basis, representing an increase of $1,256,000.
  • EBIDTA was $1,274,000 compared to an adjusted net loss of ($5,000). A table reconciling EBITDA to the appropriate GAAP measure is included with the Company's financial information below.
  • Cash provided from operations for the nine months ended September 30, 2020 and 2019 of $4,945,000, compared to cash used in operations of ($573,000), respectively.

     Balance sheet highlights as of September 30, 2020 and December 31, 2019

  • Cash and cash equivalents of approximately $5,885,000 and $897,000, representing an increase of $4,988,000.  
  • Working capital of $11,692,000 and ($1,266,000), representing an increase of $12,958,000.
  • Shareholders’ equity of $13,251,000 and $890,000, representing an increase of $12,361,000.

Current Business Highlights To Date

  • Milestone reached in the third quarter of 2020 with total revenues exceeding $21 million in a calendar year.
  • Year over year growth in overall revenue through September 30th of $16,882,000 or 376%.
  • Year over year growth SteraMist® equipment revenue through September 30th of $13,165,000 or 456%.
  • Year over year growth SteraMist® BIT Solution revenue through September 30th of $2,931,000 or 509%.
  • Year over year growth in service revenue through September 30th of $786,000 or 76%.

Business Highlights

  • Increased demand on solution re-orders as disinfecting and decontamination procedures have increased exponentially across the world.
  • Saw an increase in Hospital-Healthcare customers purchasing multiple SteraMist units in order to deploy throughout multiple locations and/or areas within a facility.
  • Broke ground on installation of permanent fogging system into our Frederick MD Facility.
  • Continued development and testing of the “SteraBot” and launch of pilot program at Lithuanian University Hospital.
  • Continued development of SteraPack with a tentative launch set for first quarter 2021.
  • Launch of Commercial Division in response to increased demand in Federal Government facilities and agencies, the aircraft (both airplane and helicopter), manufacturing companies, automobile, naval, education, retail, housing and recreation, and of course emergency preparedness for counties and cities.
  • SteraMist was featured in a United States Department of Agriculture paper “Cold plasma-activated hydrogen peroxide aerosol on populations of Salmonella Typhimurium and Listeria innocua and quality changes of apple, tomato and cantaloupe during storage – A pilot scale study” is authored by Dr. Xuetong Fan, who has previously contributed to two prior studies regarding direct produce application.
  • Issuance of a first Australian patent protecting use of its iHP technology, and pursuing patent rights in diverse regions of the world, encompassing the European Union, Brazil, Mexico, Korea, China, India, and many other countries.
  • SteraMist was chosen to be a disinfection solution for the 2019-2020 PGA Champions Tour.
  • Increased demand of product and services has led to the hiring and onboarding of additional employees to assist in a wide variety of company operations, including but not limited to accounting, procurement, customer satisfaction, and quality control.

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of  ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

For additional information, please visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

Use of Non-GAAP Financial Measures

TOMI uses a non-GAAP financial measures in this release. Earnings before interest, taxes, depreciation and amortization (EBITDA) is a non-GAAP financial measure and is intended to serve as a supplement to TOMI’s results provided in accordance with GAAP. TOMI believes that such information may provide its investors a better understanding of TOMI’s underlying operational performance, business and performance trends. 

Although TOMI believes that the use of non-GAAP financial measures enhance its investors’ understanding of its business and performance, TOMI’s use of non-GAAP financial measures should not be considered an alternative to GAAP basis financial measures and should be read in conjunction with the relevant GAAP financial measures. Other companies in similar industries may define or calculate non-GAAP financial measures differently than TOMI, limiting their usefulness as a comparative measure.  Because of these limitations, the non-GAAP financial measure used in this release should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measure is available in this news release.

 September 30, 2020
 December 31, 2019
Cash and Cash Equivalents$5,885,383 $897,223
Accounts Receivable - net3,504,284 1,494,658
Other Receivables157,487 -
Inventories4,374,500 2,315,214
Vendor Deposits333,212 141,052
Prepaid Expenses376,758 187,664
Total Current Assets14,631,624 5,035,811
Property and Equipment – net1,111,342 1,367,864
Other Assets:   
Intangible Assets – net658,969 939,010
Operating Lease - Right of Use Asset642,738 674,471
Capitalized Software Development Costs - net62,852 94,278
Other Assets469,024 114,033
Total Other Assets1,833,583 1,821,792
Total Assets$17,576,549 $8,225,467
Current Liabilities:  
Accounts Payable$2,149,988 $713,222
Accrued Expenses and Other Current Liabilities671,381 450,112
Accrued Officers Compensation40,050 -
Accrued Interest- 66,667
Current Portion of Long-Term Operating Lease78,723 71,510
Convertible Notes Payable, net of discount of $0 
at December 31, 2020- 5,000,000
Total Current Liabilities2,940,142 6,301,511
Long-Term Liabilities:  
Loan Payable410,700  
Long-Term Operating Lease, Net of Current Portion974,311 1,034,413
Total Long-Term Liabilities1,385,011 1,034,413
Total Liabilities4,325,153 7,335,924
Commitments and Contingencies- -
Shareholders’ Equity:  
Cumulative Convertible Series A Preferred Stock;
par value $0.01 per share, 1,000,000 shares authorized; 63,750 shares issued  
and outstanding at September 30, 2020 and December 31, 2019638 638
Cumulative Convertible Series B Preferred Stock; $1,000 stated value;  
7.5% Cumulative dividend; 4,000 shares authorized; none issued  
and outstanding at September 30, 2020 and December 31, 2019- -
Common stock; par value $0.01 per share, 250,000,000 shares authorized;  
16,748,513 and 15,587,552 shares issued and outstanding  
at September 30, 2020 and December 31, 2019, respectively.167,485 155,875
Additional Paid-In Capital49,287,039 44,232,274
Accumulated Deficit(36,203,766) (43,499,244)
Total Shareholders’ Equity13,251,396 889,543
Total Liabilities and Shareholders’ Equity$17,576,549 $8,225,467
(1) Share amounts have been retroactively restated to reflect the Company’s reverse stock split, which was
effected September 10, 2020. Refer to Note 11—Equity for further information.  

  For The Three Months Ended For The Nine Months Ended 
  September 30,  September 30,  
  2020 2019 2020 2019 
Sales, net$4,291,589 $1,600,387 $21,373,504 $4,491,719 
Cost of Sales1,455,568 460,008 8,484,580 1,616,680 
Gross Profit2,836,021 1,140,379 12,888,924 2,875,039 
Operating Expenses:        
Professional Fees227,560 82,945 418,516 297,349 
Depreciation and Amortization177,279 182,689 521,486 539,070 
Selling Expenses212,624 314,110 980,096 1,274,326 
Research and Development44,862 88,137 245,443 249,373 
Equity Compensation Expense10,621 - 307,686 87,033 
Consulting Fees75,204 31,799 226,454 87,066 
General and Administrative991,543 628,285 2,776,846 1,931,770 
Total Operating Expenses1,739,693 1,327,965 5,476,527 4,465,987 
Income (loss) from Operations1,096,328 (187,586) 7,412,397 (1,590,948) 
Other Income (Expense):        
Amortization of Debt Discounts- - - (17,534) 
Interest Income762 773 2,347 2,432 
Interest Expense(790) (50,000) (42,266) (150,000) 
Total Other Income (Expense)(28) (49,227) (39,919) (165,102) 
Income (loss) before income taxes1,096,300 (236,813) 7,372,478 (1,756,050) 
Provision for Income Taxes77,000 - 77,000 - 
Net Income (loss)$1,019,300 ($236,813) $7,295,478 ($1,756,050) 
Net income (loss) Per Common Share        
Basic$0.06 ($0.02) $0.44 ($0.11) 
Diluted$0.05 ($0.02) $0.40 ($0.11) 
Basic Weighted Average Common Shares Outstanding16,741,622 15,588,680 16,429,360 15,585,822 
Diluted Weighted Average Common Shares Outstanding18,593,255 15,588,680 18,280,993 15,585,822 
(1) Share and per share amounts have been retroactively restated to reflect the Company’s reverse stock split, which was effected
September 10, 2020. Refer to Note 11—Equity for further information.       


 Reconciliation of Net Income to EBITDA      
   For The Three Months Ended For The Nine Months Ended
   September 30,  September 30,
    2020   2019   2020   2019 
   (Unaudited) (Unaudited) (Unaudited) (Unaudited)
Net income (loss) $1,019,300  $(236,813)  $7,295,478  $(1,756,050) 
 Interest Income (762)   (773)   (2,347)   (2,432) 
 Interest Expense 790   50,000   42,266   150,000 
 Depreciation and Amortization 177,279   182,689   521,486   539,070 
 Provision for Income Taxes (Note 17) 77,000     77,000   
 Other  -   -   -   17,534 
 EBITDA (Adjusted Loss) $1,273,607  $(4,897)  $7,933,883  $(1,051,878) 
 EBITDA Margin  30%  0%  37%  -23%


Harold Paul